A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward et al., Global cancer statistics, CA Cancer J Clin, vol.61, pp.69-90, 2011.

J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane et al., Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, vol.359, pp.378-90, 2008.

A. Villanueva, D. Y. Chiang, P. Newell, J. Peix, S. Thung et al., Pivotal role of mTOR signaling in hepatocellular carcinoma, Gastroenterology, vol.135, pp.1-11, 2008.

M. S. Matter, T. Decaens, J. B. Andersen, and S. S. Thorgeirsson, Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends, J Hepatol, vol.60, pp.855-65, 2014.

I. Kunter, E. Erdal, D. Nart, F. Yilmaz, S. Karademir et al., Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma, Oncol Rep, vol.31, pp.573-80, 2014.

M. Laplante and D. M. Sabatini, mTOR signaling in growth control and disease, Cell, vol.149, pp.274-93, 2012.

J. Mattina, N. Mackinnon, V. C. Henderson, D. Fergusson, and J. Kimmelman, Design and reporting of targeted anti-cancer preclinical studies: a metaanalysis of animal studies investigating sorafenib antitumor efficacy, Cancer Res, vol.76, pp.4627-4663, 2016.

E. Schiffer, C. Housset, W. Cacheux, D. Wendum, C. Desbois-mouthon et al., an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis, Hepatology, vol.41, pp.307-321, 2005.

J. M. Lapierre, S. Eathiraj, D. Vensel, Y. Liu, C. O. Bull et al., -aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin -2-amine (ARQ 092): an orally bioavailable, selective, and potent allosteric AKT inhibitor, J Med Chem, vol.3, issue.3, pp.6455-69, 2016.

J. P. Thi-ery, I. Blazsek, S. Legras, S. Marion, M. Reynes et al., Hepatocellular carcinoma cell lines from diethylnitrosamine phenobarbital-treated rats. Characterization and sensitivity to endothall, a protein serine/threonine phosphatase-2A inhibitor, Hepatology, vol.29, pp.1406-1423, 1999.

B. C. Fuchs, Y. Hoshida, T. Fujii, L. Wei, S. Yamada et al., Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma, Hepatology, vol.59, pp.1577-90, 2014.

W. Sieghart, M. Pinter, B. Dauser, N. Rohr-udilova, A. C. Piguet et al., Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma, J Hepatol, vol.57, pp.592-601, 2012.

F. M. Gu, Q. L. Li, Q. Gao, J. H. Jiang, X. Y. Huang et al., Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3, World J Gastroenterol, vol.17, pp.3922-3954, 2011.

Q. Wang, G. Shi, L. Wang, X. Liu, and R. Wu, Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study, Br J Radiol, vol.87, 2014.

J. Yan, C. Tan, F. Gu, J. Jiang, M. Xu et al., Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase, Liver Transpl, vol.19, pp.507-527, 2013.

J. Rodon, R. Dienstmann, V. Serra, and J. Tabernero, Development of PI3K inhibitors: lessons learned from early clinical trials, Nat Rev Clin Oncol, vol.10, pp.143-53, 2013.

, Mol Cancer Ther, vol.16, pp.2157-2165, 2017.

S. Gaël, Z. M. Roth, A. Jilkova, and . Zeybek-kuyucu,